As BCL2 was an important determinant of survival of both myeloid progenitor and B cells, researchers investigated whether clinical and molecular abnormalities arise in the myeloid compartment during long-term continuous venetoclax treatment of chronic lymphocytic leukemia in 89 patients.
[Blood]
Sorry, but the selected Zotpress account can't be found.
